Presentation

Company Profile
Vicore Pharma is a drug development company focused on rare and deadly lung disorders where there is currently no satisfactory treatment. The firm has created and patented a unique collection of small molecules that stimulate the AT2 receptor within the Renin Angiotensin System (RAS). C21 (VP01) has been granted orphan drug status by both EMA (Europe) and FDA (U.S.). Thus far the company proved the safety and tolerability of its lead candidate in three phase 1 studies and one phase 2 study in COVID-19 patients. Further positive data proving C21’s effect have been reported in a study of an IPF lung transplant. The second drug, VP02, is a thalidomide based inhalable microparticles formulation that is set to enter clinics early next year. A third asset, also an AT2 agonist (VP03), is also expected to enter the clinics next year.

Recent highlights
The company has reported a blood-vessel dilating effect in systemic sclerosis patients with Raynaud’s phenomenon, is advancing its phase 2 trial within IPF and has initiated a phase 3 trial of C21 in COVID-19 patients.

Outlook
We expect submission of a CTA for VP02’s phase 1 trial within Q4, the topline readout of C21’s COVID-19 phase 3 trial in late Q1/Q2, the submission of a CTA for VP03’s phase 1 trial in Q1 2022 and topline readouts of VP02 in Q3 22 and C21 in IPF patients in Q4 22.